We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Nevro (NVRO) Plagued by Issues in Australia & Stiff Rivalry
Read MoreHide Full Article
On Apr 1, we issued an updated research report on Nevro Corp. (NVRO - Free Report) . Sluggishness in Australia, a highly competitive Spinal Cord Stimulation (SCS) market and a tough regulatory environment are headwinds at the moment.
The company has a negative average earnings surprise of 50.4% for the trailing four quarters.
Price Performance
A glance at the stock's price performance shows that it has declined 28.9% against the industry’s 16.1% increase. The current level is also lower than the S&P 500 index’s 10% rally.
Deterrents
In the recently-reported fourth quarter, Nevro’s international sales were negatively impacted by weakness in Australia. Management expects 2019 international revenues to remain flat owing to reimbursement changes in Australia that will begin in April 2019.
In fact, the company’s 2019 revenue guidance appears bleaks since it assumes headwinds due to reimbursement changes in Australia.
Additionally, Nevro faces stiff competition in the SCS market from MedTech bigwigs like Medtronic (MDT - Free Report) , Boston Scientific and Abbott Laboratories (ABT - Free Report) , who have already obtained regulatory approval for SCS systems and have greater capital resources.
Nevro’s products and operations are subject to extensive and rigorous regulations by the FDA under the Federal Food, Drug, and Cosmetic Act and its regulations, guidance and standards. Any violation of these could result in a material adverse effect on the company’s business, financial condition and operational results.
However, Nevro aims to continue to improve patient outcomes and expand patient access to HF10 therapy through enhancements to its flagship Senza platform. Notably, the company’s R&D expenses shot up 35.6% year over year in the recently-reported fourth quarter and 29% in 2018.
Estimate Revision
The Zacks Consensus Estimate for 2019 is pegged at a loss of $2.31. The same for revenues stands at $405.5 million, mirroring a 4.7% improvement from 2018. In fact, the company’s first-quarter earnings are expected to decline 11.9%.
Despite an R&D edge, persisting sluggishness in Australia are likely to hurt Nevro Corp. Additionally, a Zacks Rank #4 (Sell) along with a VGM Score of C is indicative of dull prospects.
A Key Pick
A better-ranked stock in the broader medical space is Penumbra, Inc. (PEN - Free Report) .
Is Your Investment Advisor Fumbling Your Financial Future?
See how you can more effectively safeguard your retirement with a new Special Report, “4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future.”
Image: Bigstock
Nevro (NVRO) Plagued by Issues in Australia & Stiff Rivalry
On Apr 1, we issued an updated research report on Nevro Corp. (NVRO - Free Report) . Sluggishness in Australia, a highly competitive Spinal Cord Stimulation (SCS) market and a tough regulatory environment are headwinds at the moment.
The company has a negative average earnings surprise of 50.4% for the trailing four quarters.
Price Performance
A glance at the stock's price performance shows that it has declined 28.9% against the industry’s 16.1% increase. The current level is also lower than the S&P 500 index’s 10% rally.
Deterrents
In the recently-reported fourth quarter, Nevro’s international sales were negatively impacted by weakness in Australia. Management expects 2019 international revenues to remain flat owing to reimbursement changes in Australia that will begin in April 2019.
In fact, the company’s 2019 revenue guidance appears bleaks since it assumes headwinds due to reimbursement changes in Australia.
Additionally, Nevro faces stiff competition in the SCS market from MedTech bigwigs like Medtronic (MDT - Free Report) , Boston Scientific and Abbott Laboratories (ABT - Free Report) , who have already obtained regulatory approval for SCS systems and have greater capital resources.
Nevro’s products and operations are subject to extensive and rigorous regulations by the FDA under the Federal Food, Drug, and Cosmetic Act and its regulations, guidance and standards. Any violation of these could result in a material adverse effect on the company’s business, financial condition and operational results.
However, Nevro aims to continue to improve patient outcomes and expand patient access to HF10 therapy through enhancements to its flagship Senza platform. Notably, the company’s R&D expenses shot up 35.6% year over year in the recently-reported fourth quarter and 29% in 2018.
Estimate Revision
The Zacks Consensus Estimate for 2019 is pegged at a loss of $2.31. The same for revenues stands at $405.5 million, mirroring a 4.7% improvement from 2018. In fact, the company’s first-quarter earnings are expected to decline 11.9%.
Nevro Corp. Price and Consensus
Nevro Corp. Price and Consensus | Nevro Corp. Quote
Bottom Line
Despite an R&D edge, persisting sluggishness in Australia are likely to hurt Nevro Corp. Additionally, a Zacks Rank #4 (Sell) along with a VGM Score of C is indicative of dull prospects.
A Key Pick
A better-ranked stock in the broader medical space is Penumbra, Inc. (PEN - Free Report) .
Penumbra’s long-term earnings growth rate is 20.9%. The stock carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Is Your Investment Advisor Fumbling Your Financial Future?
See how you can more effectively safeguard your retirement with a new Special Report, “4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future.”
Click to get it free >>